Esketamine for depression: all studies (page 7)

Intranasal Esketamine Versus Other Pharmacological Strategies in Treatment-Resistant Depression with High Suicide Risk: A Six-Month Naturalistic Study.

Clinics and practice June 12, 2026 Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.

Background: Treatment-resistant depression (TRD) poses a major clinical challenge, particularly when accompanied by suicidal behavior. Intranasal esketamine has demonstrated rapid antidepressant effects in TRD, but real-world comparative evidence remains limited. Methods: We conducted a six-month naturalistic prospective cohort study in two Spanish mental health centers, including 62 TRD...

DOI: 10.3390/clinpract16060110 Full text Esketamine Treatment-resistant depression Naturalistic study Suicidal behavior

Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.

Journal of Psychiatric Research June 12, 2026 Juliana Lima Constantino, Tobias Stephan Freimann, Jens H van Dalfsen et al.

Oral esketamine is a potentially effective and well-tolerated treatment for treatment-resistant depression (TRD). However, around 50% of TRD individuals treated with oral esketamine do not achieve response, and this variation in response may be accounted for by interindividual differences between patients. Efforts to develop effective and personalized depression treatment strategies are...

DOI: 10.1016/j.jpsychires.2026.06.013 Full text Esketamine Major depressive disorder Treatment-resistant depression Antidepressants +1

Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.

European psychiatry : the journal of the Association of European Psychiatrists June 10, 2026 Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.

Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...

DOI: 10.1192/j.eurpsy.2026.12233 Full text Esketamine Treatment-resistant depression Functional remission Long-term outcomes +1

[Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects].

Fortschritte der Neurologie-Psychiatrie June 8, 2026 Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.

Introduction: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). Historically, the development of EN resulted from the positive results of randomized clinical trials on the off-label use of subnarcotic ketamine infusions (SKI) for TRD. How effective, tolerable, and safe is off-label SKI compared to EN? Methods: Narrativ...

DOI: 10.1055/a-2846-4275

Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance.

Journal of Affective Disorders June 8, 2026 Dian‐jeng Li, Tien-Wei Hsu, Te-Chang Changchien et al.

Little is known about esketamine's effectiveness for patients with major depressive disorder (MDD) comorbid substance use disorders (SUD). We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults aged ≥18 years with MDD. Three propensity-score-matched (1:1) cohorts were defined based on treatment: esketamine, antidepressant-only, and repetitive...

DOI: 10.1016/j.jad.2026.122106 Full text Esketamine Major depressive disorder Substance use disorder Mortality +1

Comparing transcranial magnetic stimulation and esketamine treatment response trajectories in resistant depression.

Journal of Affective Disorders June 7, 2026 Lindsay L Benster, Jordan N Kohn, Benjamin Wade et al.

Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are FDA-approved for treatment-resistant depression (TRD), yet comparative real-world data on response trajectories and predictors of outcomes remain limited. A retrospective analysis was performed using electronic medical records from UC San Diego Health. Adults with TRD treated with rTMS (n = 279) or intranasal...

DOI: 10.1016/j.jad.2026.122107 Full text Esketamine Treatment-resistant depression Rtms

Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review.

Journal of psychopharmacology (Oxford, England) June 2026 Vasilios G Masdrakis, Zoe Tebbs, Vasilios Natsis et al.

Ketamine and esketamine ("es/ketamine") treatment protocols have been investigated in patients' samples with treatment-refractory anxiety disorders. We systematically reviewed publications in which es/ketamine was used to treat anxiety symptoms in the context of either Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) anxiety disorders or treatment-resistant...

DOI: 10.1177/02698811251389583 Full text Esketamine Anxiety disorders Anxious depression Treatment-refractory anxiety

Effectiveness and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Early Outcomes from Poland’s First Psychiatric Drug Program B.147

European Psychiatry June 1, 2026 O. Płaza, Robert Madejek, M. M. Dutsch-Wicherek et al.

Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...

DOI: 10.1192/j.eurpsy.2026.10418

Long-Term Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: A Real-World, Single-arm Study of Over 100 sessions

European Psychiatry June 1, 2026 Nawfel Ayad, Samer Makhoul

Introduction Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce Objectives This study aimed to evaluate the long-term effectiveness and tolerability of...

DOI: 10.1192/j.eurpsy.2026.10598

What is the current status of research for esketamine in the treatment of bipolar depression? A literature review

European Psychiatry June 1, 2026 O. Vasiliu, D. G. Vasiliu

Introduction Hopes related to esketamine have been raised by its approval for treatment-resistant major depression (TRD) in the sense that this antidepressant, with a novel mechanism of action, will be useful for patients with bipolar depression (BD), too. The need to find more evidence-based pharmacological approaches to both TRD and BD is acute due to the high rates of partial response or...

DOI: 10.1192/j.eurpsy.2026.11764